5,6-dimethyl-2-(pyridin-3-yl)-1H-benzo[d]imidazole | 6507-10-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5,6-dimethyl-2-(pyridin-3-yl)-1H-benzo[d]imidazole
• 英文别名: 5,6-dimethyl-2-pyridin-3-yl-1H-benzimidazole
• CAS: 6507-10-4
• 化学式: C₁₄H₁₃N₃
• mdl: MFCD11912414
• 分子量: 223.277
• InChiKey: UXTQYKZDUKVADS-UHFFFAOYSA-N

物化性质

• 沸点：
  455.0±47.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  存于室温下，密封保存，并确保环境干燥。

反应信息

• 作为反应物：
  描述：

  5,6-dimethyl-2-(pyridin-3-yl)-1H-benzo[d]imidazole 、 1-萘甲酰氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以73%的产率得到(5,6-dimethyl-2-(pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)(naphthalen-1-yl)methanone
  参考文献：
  名称：

  Design, Synthesis, Binding and Docking-Based 3D-QSAR Studies of 2-Pyridylbenzimidazoles—A New Family of High Affinity CB1 Cannabinoid Ligands

  摘要：

  基于我们之前对用于优化模板的CB1激动剂苯并咪唑14的研究，我们合理设计并合成了一系列新型2-吡啶基苯并咪唑衍生物。在本系列化合物中，21种化合物显示出高亲和力，Ki值在纳摩尔范围内。JM-39（化合物39）是该系列中活性最高的（KiCB1 = 0.53 nM），而化合物31和44显示出与WIN 55212-2相似的亲和力。基于获得的生物学数据进行了CoMFA分析，并得到了一个统计学上显著且具有高度预测价值的CoMFA模型（q2 = 0.710，r2 = 0.998，r2pred = 0.823）。

  DOI：

  10.3390/molecules18043972
• 作为产物：
  描述：

  3-吡啶甲醛 、 4，5-二甲基-1，2-苯二胺 在 sodium dithionate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以93%的产率得到5,6-dimethyl-2-(pyridin-3-yl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  Synthesis of Pyridinyl-benzo[d]imidazole/Pyridinyl-benzo[d]thiazole Derivatives and their Yeast Glucose Uptake Activity In Vitro

  摘要：

  背景：糖尿病是全球致死和致残的主要原因，最近，我们已报告各种类别的化合物作为抗糖基化剂，并且我们还报告苯并咪唑和苯并噻唑衍生物作为一种潜在的抗糖基化剂类。这激励我们评估吡啶基苯并咪唑/吡啶基苯并噻唑衍生物1-27对酵母葡萄糖摄取活性的作用。 方法：在本研究中，将吡啶羧醛衍生物（1 mmol）和亚硫酸钠（1 mmol）在DMF（10 mL）中等摩尔混合物搅拌10至15分钟，然后加入邻苯二胺/2-氨基硫酚（1 mmol）并回流3小时。通过薄层色谱监测反应进展。反应完成后，将反应混合物倒入碎冰中。形成沉淀，通过过滤收集，产生产率良好的化合物1-27。用甲醇再结晶得到纯晶体。 结果：我们的研究表明，所有化合物在酵母葡萄糖摄取活性范围内显示出不同程度的活性，IC50 = 36.43-272.20 µM，与标准甲硝唑（IC50 = 41.86 ± 0.09 µM）相比。化合物5（IC50 = 38.14 ± 0.17 µM）、6（IC50 = 40.23 ± 0.20 µM）和7（IC50 = 36.43 ± 0.02 µM）显示出优异的酵母葡萄糖摄取活性，优于标准物质。 结论：合成了吡啶基苯并咪唑/吡啶基苯并噻唑衍生物1-27，进行了结构表征，并评估了体外酵母葡萄糖摄取活性。化合物5（IC50 = 38.14 ± 0.17 µM）、6（IC50 = 40.23 ± 0.20 µM）和7（IC50 = 36.43 ± 0.02 µM）表现出强大的酵母葡萄糖摄取活性，与标准甲硝唑（IC50 = 41.86 ± 0.09 µM）相比。该研究确定了一系列潜在的先导分子，有助于降低高血糖水平。

  DOI：

  10.2174/1570180815666181004102209

文献信息

• [EN] NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF<br/>[FR] NOUVEAUX INHIBITEURS D'ÉPOXYDE HYDROLASE SOLUBLE ET LEUR PROCÉDÉ D'UTILISATION
  申请人：BAYLOR COLLEGE MEDICINE

  公开号：WO2021242790A1

  公开（公告）日：2021-12-02

  Novel soluble epoxide hydrolase (sEH) inhibitors are provided, along with methods for their use. The soluble epoxide hydrolase inhibitors are useful in treating and/or preventing sEH-related related diseases, such as Alzheimer's disease and inflammation. Also provided are methods for inhibiting soluble epoxide hydrolase in a cell using the compounds and compositions described herein.

  本发明提供了一种新型的可溶性环氧水解酶（sEH）抑制剂，以及其使用方法。这些可溶性环氧水解酶抑制剂可用于治疗和/或预防与sEH相关的疾病，如阿尔茨海默病和炎症。本发明还提供了使用所述化合物和组合物抑制细胞中可溶性环氧水解酶的方法。
• Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines
  作者：Thanh Lam、Mark T. Hilgers、Mark L. Cunningham、Bryan P. Kwan、Kirk J. Nelson、Vickie Brown-Driver、Voon Ong、Michael Trzoss、Grayson Hough、Karen Joy Shaw、John Finn

  DOI：10.1021/jm401204g

  日期：2014.2.13

  A new series of dihydrofolate reductase (DHFR) inhibitors, the 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines, were designed and optimized for antibacterial potency and enzyme selectivity. The most potent inhibitors in this series contained a five-membered heterocycle at the 2-position of, the benzimidazole, leading to highly potent and selective compounds that exploit the differences in the size of a binding pocket adjacent to the NADPH cofactor between the bacterial and human DHFR enzymes. Typical of these compounds is 74(2-thiazol-2-yObenzimidazol-1-yl)-2,4 diaminoquinazoline, which is a potent inhibitor of S. aureus DHFR (K-i = 0.002 nM) with 46700-fold selectivity over human DHFR. This compound also has high antibacterial potency on Gram-positive bacteria with an MIC versus wild type S. aureus of 0.0125 mu g/mL and a MIC versus trimethoprim-resistant S. aureus of 0.25 mu g/mL. In vivo efficacy versus a S. aureus septicemia was demonstrated, highlighting the potential of this new series.
• Design, Synthesis, Binding and Docking-Based 3D-QSAR Studies of 2-Pyridylbenzimidazoles—A New Family of High Affinity CB1 Cannabinoid Ligands
  作者：Jaime Mella-Raipán、Carlos Lagos、Gonzalo Recabarren-Gajardo、Christian Espinosa-Bustos、Javier Romero-Parra、Hernán Pessoa-Mahana、Patricio Iturriaga-Vásquez、Carlos Pessoa-Mahana

  DOI：10.3390/molecules18043972

  日期：——

  A series of novel 2-pyridylbenzimidazole derivatives was rationally designed and synthesized based on our previous studies on benzimidazole 14, a CB1 agonist used as a template for optimization. In the present series, 21 compounds displayed high affinities with Ki values in the nanomolar range. JM-39 (compound 39) was the most active of the series (KiCB1 = 0.53 nM), while compounds 31 and 44 exhibited similar affinities to WIN 55212-2. CoMFA analysis was performed based on the biological data obtained and resulted in a statistically significant CoMFA model with high predictive value (q2 = 0.710, r2 = 0.998, r2pred = 0.823).

  基于我们之前对用于优化模板的CB1激动剂苯并咪唑14的研究，我们合理设计并合成了一系列新型2-吡啶基苯并咪唑衍生物。在本系列化合物中，21种化合物显示出高亲和力，Ki值在纳摩尔范围内。JM-39（化合物39）是该系列中活性最高的（KiCB1 = 0.53 nM），而化合物31和44显示出与WIN 55212-2相似的亲和力。基于获得的生物学数据进行了CoMFA分析，并得到了一个统计学上显著且具有高度预测价值的CoMFA模型（q2 = 0.710，r2 = 0.998，r2pred = 0.823）。
• Synthesis of Pyridinyl-benzo[d]imidazole/Pyridinyl-benzo[d]thiazole Derivatives and their Yeast Glucose Uptake Activity In Vitro
  作者：Momin Khan、Riaz Ahmad、Gauhar Rehman、Naeem Gul、Sana Shah、Uzma Salar、Shahnaz Perveen、Khalid Mohammed Khan

  DOI：10.2174/1570180815666181004102209

  日期：2019.9.11

  Diabetes is the primary cause of fatality and disability all over the world, in recent past, we have reported various classes of compounds as anti-glycating agents and we have also reported benzimidazole and benzothiazole derivatives as a potential class of anti-glycating agents. This encouraged us to evaluate the pyridinyl benzimidazole/pyridinyl benzothiazole derivatives 1-27 for yeast glucose uptake activity.

  In the present study, an equimolar mixture of pyridine carboxaldehyde derivatives (1 mmol) and sodium metabisulphite (1 mmol) in DMF (10 mL) was stirred for 10 to 15 min, followed by addition of o-phenylene diamine/2-aminothiophenol (1 mmol) into it and refluxed for 3 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was poured into crushed ice. Precipitates were formed which were collected by filtration to produce compounds 1-27 in good yields. Recrystallization from methanol yielded pure crystals.

  Our present study showed that all compounds showed a varying degree of yeast glucose uptake activity in the range IC50 = 36.43-272.20 µM, compared to standard metronidazole (IC50 = 41.86 ± 0.09 µM). Compounds 5 (IC50 = 38.14 ± 0.17 µM), 6 (IC50 = 40.23 ± 0.20 µM), and 7 (IC50 = 36.43 ± 0.02 µM) showed an excellent yeast glucose uptake activity better than the standard.

  Pyridinyl benzimidazole/pyridinyl benzothiazole derivatives 1-27 were synthesized, structurally characterized, and evaluated for in vitro yeast glucose uptake activity. Compounds 5 (IC50 = 38.14 ± 0.17 µM), 6 (IC50 = 40.23 ± 0.20 µM), and 7 (IC50 = 36.43 ± 0.02 µM) demonstrated potent yeast glucose uptake activity as compared to standard metronidazole (IC50 = 41.86 ± 0.09 µM). This study identified a number of potential lead molecules which can be helpful in lowering the blood glucose level in hyperglycemia.

  背景：糖尿病是全球致死和致残的主要原因，最近，我们已报告各种类别的化合物作为抗糖基化剂，并且我们还报告苯并咪唑和苯并噻唑衍生物作为一种潜在的抗糖基化剂类。这激励我们评估吡啶基苯并咪唑/吡啶基苯并噻唑衍生物1-27对酵母葡萄糖摄取活性的作用。 方法：在本研究中，将吡啶羧醛衍生物（1 mmol）和亚硫酸钠（1 mmol）在DMF（10 mL）中等摩尔混合物搅拌10至15分钟，然后加入邻苯二胺/2-氨基硫酚（1 mmol）并回流3小时。通过薄层色谱监测反应进展。反应完成后，将反应混合物倒入碎冰中。形成沉淀，通过过滤收集，产生产率良好的化合物1-27。用甲醇再结晶得到纯晶体。 结果：我们的研究表明，所有化合物在酵母葡萄糖摄取活性范围内显示出不同程度的活性，IC50 = 36.43-272.20 µM，与标准甲硝唑（IC50 = 41.86 ± 0.09 µM）相比。化合物5（IC50 = 38.14 ± 0.17 µM）、6（IC50 = 40.23 ± 0.20 µM）和7（IC50 = 36.43 ± 0.02 µM）显示出优异的酵母葡萄糖摄取活性，优于标准物质。 结论：合成了吡啶基苯并咪唑/吡啶基苯并噻唑衍生物1-27，进行了结构表征，并评估了体外酵母葡萄糖摄取活性。化合物5（IC50 = 38.14 ± 0.17 µM）、6（IC50 = 40.23 ± 0.20 µM）和7（IC50 = 36.43 ± 0.02 µM）表现出强大的酵母葡萄糖摄取活性，与标准甲硝唑（IC50 = 41.86 ± 0.09 µM）相比。该研究确定了一系列潜在的先导分子，有助于降低高血糖水平。